Results from a recent Phase 2 trial indicate that the com­bi­na­tion of Kyprolis, Revlimid, and dexa­meth­a­sone is effective in re­lapsed multi­ple myeloma patients.

Specifically, the results show that 77 per­cent of patients responded to the treat­ment. The investigators point out the responses seen in the trial were rapid (median time to response was one month) and robust (medi­an duration of response was 22 months).

According to the investigators, the results are particularly encouraging because one-quarter of the patients were refractory (resistant) to Velcade (bor­tez­o­mib) and almost half were refractory to …

A recent Greek study looks at the efficacy and safety of Revlimid plus dexa­metha­sone for re­lapsed and refractory multiple myeloma patients in ‘the real world’ -- that is, in patients being treated in standard clin­i­cal practice rather than clin­i­cal trials.

The study's findings con­firm that Revlimid (lena­lido­mide) plus dexa­metha­sone (Decadron) is effective and safe in day-to-day use among re­lapsed myeloma patients.

The majority of the patients in the study (77 per­cent) responded to treat­ment with Revlimid and dexa­metha­sone, with 20 per­cent achieving a com­plete response. According to the investigators, these …

Poma­lido­mide plus low-dose dexa­metha­sone dem­onstrated sig­nif­i­cantly longer median pro­gres­sion-free survival and over­all survival at a median follow-up of 10 months

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ:CELG), today announced that updated results from MM-003, a phase III multi-center, ran­dom­ized open-label study (n=455) of poma­lido­mide (marketed as POMALYST^® in the U.S. and IMNOVID^® in the E.U.) plus low-dose dexa­metha­sone, were published online ahead of print in The Lancet Oncology.

The study compared oral poma­lido­mide plus low-dose dexa­metha­sone with high-dose dexa­metha­sone in patients with refractory or re­lapsed and refractory multiple myeloma who have failed at least two prior thera­pies with both bor­tez­o­mib and lena­lido­mide, ad­min­is­tered alone or in …

Stockholm (Press Release) - Oncopeptides AB, a com­pany work­ing to en­hance on­col­ogy ther­a­pies, to­day an­nounced that the first patient has been dosed as part of a Phase II study in mul­ti­ple myeloma patients with its drug can­di­date melflufen (previously called J1).

The trial is an open-label Phase II study de­signed to de­ter­mine the level of ef­fi­cacy of melflufen in com­bi­na­tion with dexa­meth­a­sone, for late stage, relapsing or relapsing/refractory patients. The pri­mary end point is, best re­sponse in accordance with the Inter­na­tional Myeloma Work­ing Group criteria during up to eight cycles of treat­ment.

The trial is being …

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ: CELG) today announced that the European Com­mis­sion (EC) has granted approval for Poma­lido­mide Celgene^® (poma­lido­mide), in com­bi­na­tion with dexa­meth­a­sone, for the treat­ment of re­lapsed and refractory multiple myeloma (rrMM) in adult patients who have received at least two prior ther­a­pies in­­clud­ing both lena­lido­mide and bor­tez­o­mib and have dem­onstrated disease pro­gres­sion on the last ther­apy.¹ Celgene intends to launch Poma­lido­mide Celgene in the EU under the trade name “IMNOVID^®”, fol­low­ing sub­mission of a regu­la­tory notification to the European Medicines …

Results from a small Phase 2 study conducted throughout Japan sug­gest that a com­bi­na­tion of Velcade, doxorubicin, and intermediate-dose dexa­meth­a­sone is effective in patients with re­lapsed or refractory multiple myeloma.

Most patients (89 per­cent) responded to treat­ment, with a third of them achieving a com­plete or near com­plete response.  In addi­tion, the medi­an pro­gres­sion-free survival was 12.1 months.

According to the Japanese researchers, the findings from this study are com­par­able to those from pre­vi­ous studies that examined the effective­ness of the Velcade (bor­tez­o­mib), doxorubicin (Adriamycin), and

• Median progression-free survival (PFS) of 33 months reached after longer-term follow up in patients treated with elotuzumab 10 mg/kg plus lenalidomide and low-dose dexamethasone
• Longer-term safety profile of the combination consistent with previously reported results
• Results Presented at 18th Annual Congress of the European Hematology Association
• Two Phase 3 studies of elotuzumab at 10 mg/kg dose ongoing in patients with previously-treated and newly-diagnosed multiple myeloma

Princeton, NJ and North Chicago, IL (Press Release) – Bristol-Myers Squibb Com­pany (NYSE: BMY) and AbbVie (NYSE: ABBV) to­day an­nounced up­dated ef­fi­cacy and safety data from a small, ran­dom­ized Phase 2, open-label study in patients with pre­vi­ously-treated mul­ti­ple myeloma that eval­u­ated two doses of the inves­ti­ga­tional mono­clonal anti­body elotuzumab (10 mg/kg and 20 mg/kg) in com­bi­na­tion with lena­lido­mide and low-dose dexa­meth­a­sone. In the 10 mg/kg arm (N=36), which is the dose used in the on­go­ing Phase 3 trials, median pro­gres­sion-free sur­vival (PFS), or the time without dis­ease pro­gres­sion, …